Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
IntegraGen logo — Company specializing in the genomics of cancer and genetic d...

IntegraGen

Company specializing in the genomics of cancer and genetic diseases

Founded 2000 France France 50 employees Post-IPO Equity Total: $12.40M Biotechnology, Health Care +1

General Information

Company Name IntegraGen
Founded Year 2000
Location France France
Employees 50
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with IntegraGen. To contact IntegraGen, visit integragen.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About IntegraGen

IntegraGen is a France-based company specializing in the genomics of cancer and rare genetic diseases. It is a part of the OncoDNA group and boasts highly competent teams, making it a leading player in DNA sequencing services and genomic data interpretation software. The company, founded in 2000, operates one of the largest NGS labs in France and collaborates with esteemed research institutes. With around 50 employees, IntegraGen generated €9 million in revenue in 2020. It also has a presence in the United States and is backed by an international network of 35 distributors through the OncoDNA group. IntegraGen, listed on Euronext Growth in Paris (ISIN: FR0010908723 - Mnemo: ALINT - Eligible PEA-PME), is dedicated to leveraging next generation sequencing to deliver precision medicine to patients. The company, being a part of the OncoDNA group, also provides biomarker testing and clinical interpretation tools for the treatment and monitoring of late stage solid tumors and to aid in the development of new cancer drugs. The most recent investment in IntegraGen was a $2.40M Post-IPO Equity investment on 13 July 2012.

Taxonomy: Genomics, Cancer Research, DNA Sequencing, Precision Medicine, Bioinformatics, NGS (Next Generation Sequencing), Biomarker Testing, Clinical Interpretation, Molecular Markers, Biotech Services, Pharmaceutical Research, Rare Genetic Diseases, Metabolic Diseases, Oncology, Sequencing Services

Services & Products

Genome Sequencing
RNA Sequencing
Methylation Analysis
Bioinformatics Analysis
NGS Sequencing
Genotyping

Target Customers

Researchers Clinicians Academic Laboratories Biopharmaceutical Companies Clinical Research Organizations

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $2.40M -
13 Jul 2012
Venture Round Undisclosed 5
Generis Capital Partners Innovation Capital
Generis Capital Partners, Innovation Capital +3
06 Jun 2010
Venture Round €2.00M 1
DSM Venturing
DSM Venturing
06 Nov 2006
Series B €8.00M 4
IDInvest Partners Bioam Gestion
IDInvest Partners, Bioam Gestion +2
17 Nov 2005

IntegraGen Alternatives & Competitors

View All Alternatives
IntegraGen vs
OncoDNA
OncoDNA Belgium

Genomic and theranostic company specializing in precision medicine for the treatment of cancer and g...

Series C
52 employees
Biotechnology, Health Care
Compare IntegraGen vs OncoDNA
IntegraGen vs
Annoroad Genomics
Annoroad Genomics China

Annoroad, headquartered in Beijing, is the China’s leading developer and marketer on genomic innovat...

Series C
16 employees
Biotechnology, Health Care
IntegraGen vs
Malaysian Genomics Resource Centre Berhad
Malaysian Genomics Resource Centre Berhad Malaysia

Genomics and biopharmaceutical company providing improved access to the latest immunotherapy and hea...

25 employees
Biotechnology, Health Care
View all alternatives

FAQ About IntegraGen

Company specializing in the genomics of cancer and genetic diseases
IntegraGen was founded in 2000.
IntegraGen is headquartered in France.
IntegraGen operates in Biotechnology, Health Care and Health and Wellness. Its work centres on Genomics, Cancer Research, DNA Sequencing and Precision Medicine. Its customers include Researchers, Clinicians and Academic Laboratories.
IntegraGen has approximately 50 employees.
IntegraGen has completed 4 funding rounds, raising a total of $12.40M. The latest funding stage is Post-IPO Equity.
IntegraGen offers: Genome Sequencing, RNA Sequencing, Methylation Analysis, Bioinformatics Analysis, NGS Sequencing, Genotyping.
Top alternatives and competitors to IntegraGen include OncoDNA, Annoroad Genomics, Malaysian Genomics Resource Centre Berhad, TwinStrand Biosciences, Aniling. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
IntegraGen and OncoDNA are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for IntegraGen, https://bouncewatch.com/company/oncodna-integragen, updated 7 June 2025. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes